Stock IRLAB THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company IRLAB Therapeutics AB Nasdaq Stockholm

Equities

Pharmaceuticals

End-of-day quote Nasdaq Stockholm
Other stock markets
- SEK - Intraday chart for IRLAB Therapeutics AB
05-27 Sweden’s IRLAB Therapeutics Names New CEO MT
05-27 IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 CI

Business Summary

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Sales per Business

SEK in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
61 100.0 % 6 100.0 % -90.71%

Sales per region

SEK in Million2022Weight2023Weight Delta
United States
74.3 %
-- 4 74.3 % -
United Kingdom
25.7 %
61 100.0 % 1 25.7 % -97.62%

Managers

Managers TitleAgeSince
Clas Sonesson FOU
 Founder 63 31/12/12
Gunnar Olof Olsson CEO
 Chief Executive Officer 71 05/05/17
Nicholas Waters FOU
 Founder 62 31/12/12
Erik Viktor Siewertz DFI
 Director of Finance/CFO 53 31/12/12
Peder Svensson CTO
 Chief Tech/Sci/R&D Officer 62 31/12/15
Joakim Tedroff CTO
 Chief Tech/Sci/R&D Officer 63 31/12/15
Susanna Waters PRN
 Corporate Officer/Principal 58 -

Members of the board

Members of the board TitleAgeSince
Jan Anders Vedin BRD
 Director/Board Member 82 31/12/15
Rein Piir BRD
 Director/Board Member 66 31/12/15
Carola Elisabet Lemne CHM
 Chairman 66 31/03/19
Gunnar Olof Olsson CEO
 Chief Executive Officer 71 05/05/17
Christer Nordstedt BRD
 Director/Board Member 62 31/12/22
Veronica Wallin BRD
 Director/Board Member 38 31/12/22
Daniel Johnsson BRD
 Director/Board Member 56 31/12/22
Catharina Gustafsson Wallich BRD
 Director/Board Member 60 31/12/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 79,776 0 0 57.48 %
Stock B 1 51,788,630 29,815,943 ( 57.57 %) 0

Shareholders

NameEquities%Valuation
Daniel Johnsson
8.729 %
4,520,400 8.729 % 5 M kr
Ancoria Insurance Ltd.
7.389 %
3,826,638 7.389 % 4 M kr
FV Group AB
7.078 %
3,665,626 7.078 % 4 M kr
Fjärde AP-fonden
6.749 %
3,495,420 6.749 % 4 M kr
Futur Pension Försäkringsaktiebolag
3.969 %
2,055,484 3.969 % 2 M kr
Unionen (Investment Management)
3.862 %
2,000,000 3.862 % 2 M kr
Tredje AP-fonden
3.568 %
1,847,994 3.568 % 2 M kr
Philip Diklev
2.929 %
1,517,106 2.929 % 2 M kr
Marinvest Holding AB
2.333 %
1,208,250 2.333 % 1 M kr
Hans Victor
2.033 %
1,052,699 2.033 % 1 M kr
NameEquities%Valuation
Nicholas Waters
11.21 %
8,946 11.21 % 9 292 kr
Susanna Waters
11.21 %
8,946 11.21 % 9 292 kr
Peder Svensson
11.21 %
8,946 11.21 % 9 292 kr
Cecilia Tivert Stenberg
11.21 %
8,946 11.21 % 9 292 kr
Joakim Tedroff
11.21 %
8,946 11.21 % 9 292 kr
Clas Sonesson
11.21 %
8,946 11.21 % 9 292 kr
Rein Piir
6.978 %
5,567 6.978 % 5 782 kr

Company contact information

IRLAB Therapeutics AB

Arvid Wallgrens Backe 20

413 46, Gothenburg

+46 3 17 57 38 00

http://www.irlab.se
address IRLAB Therapeutics AB

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IRLAB A Stock
  4. Stock
  5. Company IRLAB Therapeutics AB